STEPHEN DRESKIN, MD
Osteopathic Medicine at 16 Ave, Denver, CO

2003002, Jan 30, 2003

May 29, 2002

10/158568

Stephen Dreskin - Denver CO, US
Donald Dibbern - Tigard OR, US
Phillip Williams - Olathe KS, US

G01N033/567

435/007210

The present assays provide ex vivo methods for determining a significant and potentially life threatening response of mast cells and/or basophils of a patient to one or more antigens, where the response is mediated by IgE and the Fc RI protein binding and serotonin, histamine or other signaling or mediator of IgE-allergen binding. Cells which express IgE and Fc RI are labeled by uptake of detectable 5-hydroxytryptamine (serotonin) or other signaling compound, and the release of the intracellular pool of detectable compound is triggered by the addition of the allergen to which sensitivity is observed. Significant release in response to a particular compound or composition indicates that there is potentially danger to the patient from whom the cells were prepared if that patient comes in contact with the allergen. The assay can also be manipulated to detect the presence of a potentially dangerous allergen in a composition. Significant release of the detectable signaling compound, especially radiolabeled 5-HT, in response to a composition or compound indicates that there is the potential for a dangerous response to the composition or particular allergen.

2014008, Mar 20, 2014

Mar 20, 2012

14/006448

Stephen C. Dreskin - Denver CO, US
Kanao Otsu - Denver CO, US

The Regents of the University of Colorado, a body corporate - Denver CO

G01N 33/68

506 9, 436501

The present invention provides methods for determining a likelihood of a degree of allergic reaction or a severity thereof using a threshold value rather than the binding activity number between the immunoglobulin of the subject and a test composition comprising a marker protein moiety of the allergy inducing material. In one particular embodiment of the invention, methods are provided for determining a likelihood of a degree of allergic reaction severity of a subject to peanuts using a threshold value of binding between immunoglobulin E (IgE) of the subject and Ara h 2 moiety and Ara h 6 moiety.

2013019, Aug 1, 2013

Nov 27, 2012

13/686877

The Regents of the University of Colorado, A Body - Denver CO, US
Miguel A. Lanaspa-Garcia - Denver CO, US
Stephen Dreskin - Denver CO, US

The Regents of the University of Colorado, A Body Corporate - Denver CO

A61K 38/14, A61K 45/00

4241581, 514 31

Provided are methods and compositions method for inhibiting fructokinase activity within the gastrointestinal tract cell of a subject. The compositions and methods treat or prevent conditions associated with increased permeability and oxidative stress in the gastrointestinal tract of a subject.